N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of
Brivaracetam (BRV); as well as the effect of BRV on subjects' health-related quality of life
and to explore the direct medical resource use for BRV (for subjects entering N01372 from a
study where pharmacoeconomic data was collected). BRV will be used at doses up to maximum of
200 mg/day, as adjunctive treatment in subjects aged 16 years or older with Epilepsy.